You are here

bladder cancer

Merck Plans New Facility to Triple Production of Life-Saving Bladder Cancer Drug

Merck Plans New Facility to Triple Production of Life-Saving Bladder Cancer Drug

BioSpace

drug manufacturing

Flag link:

Bristol Myers Squibb's Opdivo cuts relapse risk in muscle-invasive bladder cancer

Bristol Myers Squibb's Opdivo cuts relapse risk in muscle-invasive bladder cancer

Fierce Pharma

Bristol-Myers Squibb

Flag link:

ESMO: Merck's Keytruda-chemo combo shows survival 'trend,' but can't top chemo in bladder cancer

ESMO: Merck's Keytruda-chemo combo shows survival 'trend,' but can't top chemo in bladder cancer

Fierce Pharma

metastatic bladder cancer

Flag link:

Seattle Genetics stays step ahead of rivals with bladder cancer data

Seattle Genetics stays step ahead of rivals with bladder cancer data

BioPharma Dive

Seattle Genetics

clinical trials

Flag link:

AZ aims to cut cancer clinic visits with new Imfinzi regimen

AZ aims to cut cancer clinic visits with new Imfinzi regimen

Pharmaforum

Flag link:

Merck & Co’s Keytruda fails in first line bladder cancer

Merck & Co’s Keytruda fails in first line bladder cancer

Pharmaforum

Flag link:

ASCO: Pfizer, Merck KGaA's Bavencio posts win in rare gynecological cancer

ASCO: Pfizer, Merck KGaA's Bavencio posts win in rare gynecological cancer

Fierce Pharma

gestational trophoblastic tumors

clinical trials

Flag link:

Seattle Genetics' bladder cancer med Padcev blows early expectations out of the water

Seattle Genetics' bladder cancer med Padcev blows early expectations out of the water

Fierce Pharma

Seattle Genetics

Flag link:

Seattle could waltz in where Astra failed

Seattle could waltz in where Astra failed

EP Vantage

Seattle Genetics

clinical trials

Flag link:

Pharma New Astellas, Seattle Genetics Padcev combo data spark $5.8B sales hopes

Pharma New Astellas, Seattle Genetics Padcev combo data spark $5.8B sales hopes

Fierce Pharma

Seattle Genetics

advanced bladder cancer

Flag link:

Seattle Genetics, Astellas Says 73% Of Bladder Cancer Patients On Padcev Had Confirmed Tumor Response

Seattle Genetics, Astellas Says 73% Of Bladder Cancer Patients On Padcev Had Confirmed Tumor Response

Reuters

Seattle Genetics

Flag link:

Roche's Tecentriq fails trial in form of urothelial cancer

Roche's Tecentriq fails trial in form of urothelial cancer

Reuters

clinical trials

urothelial cancer

Flag link:

Merck's Blockbuster Drug Wins Key New FDA Approval

Merck's Blockbuster Drug Wins Key New FDA Approval

Motley Fool

Flag link:

Merck KGaA, Pfizer's Bavencio set to seal bladder cancer approval after confirmatory trial scores

Merck KGaA, Pfizer's Bavencio set to seal bladder cancer approval after confirmatory trial scores

Endpoints

Flag link:

Merck’s Keytruda nabs FDA panel's favor to line up for new bladder cancer OK

Merck’s Keytruda nabs FDA panel's favor to line up for new bladder cancer OK

Fierce Pharma

Flag link:

FerGene’s Bladder Cancer Phase III Trial Hits Its Mark

FerGene’s Bladder Cancer Phase III Trial Hits Its Mark

BioSpace

Ferring Pharmaceuticals

Blackstone Life Sciences

clinical trials

Flag link:

Merck’s Keytruda gets FDA priority review for high-risk NMIBC

Merck’s Keytruda gets FDA priority review for high-risk NMIBC

Pharmaceutical Business Review

priority review

Flag link:

ESMO: Astellas, Seattle Genetics' Keytruda combo shrinks 71% of bladder cancers

ESMO: Astellas, Seattle Genetics' Keytruda combo shrinks 71% of bladder cancers

Fierce Biotech

Seattle Genetics

enfortumab vedotin

urothelial cancer

Flag link:

Oncologists listen when the FDA speaks, even after a drug hits the market

Oncologists listen when the FDA speaks, even after a drug hits the market

Endpoints

Flag link:

Sesen Bio reports data update from phase 3 trial for high-risk non-muscle invasive bladder cancer

Sesen Bio reports data update from phase 3 trial for high-risk non-muscle invasive bladder cancer

Pharmaceutical Business Review

clinical trials

Flag link:

Pages